On November 16, 2026 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to onvansertib in combination with FOLFIRI/bevacizumab (bev) for the first-line treatment of adult patients with KRAS- or NRAS-mutated metastatic colorectal cancer (mCRC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need," said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. "Our randomized Phase 2 data give us confidence that onvansertib may provide an additive benefit to the current standard-of-care, as reflected in the maturing data from the ongoing trial. We look forward to working closely with the FDA as we advance onvansertib into our planned registrational trial and bringing this potential new treatment option to patients as quickly as possible."
The Fast Track designation is supported by data from the Company’s ongoing randomized Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC. The proposed Phase 3 regimen, 30 mg onvansertib + FOLFIRI/bev, achieved a 72.2% confirmed objective response rate, a 30-point improvement over FOLFIRI/bev alone (42.1%) in the intent-to-treat population. As of September 28, 2026, median progression-free survival had not been reached in the 30 mg arm, compared with approximately 11 months in the combined standard-of-care arms, and all patients remaining in the 30 mg arm have now been on treatment for at least 21 months. These results build on a prior Phase 1b/2 trial in second-line KRAS-mutated mCRC.
This designation also follows the FDA’s recent grant of Orphan Drug Designation to onvansertib for the treatment of chronic myelomonocytic leukemia and small cell lung cancer in October and November 2026, respectively.
About Fast Track Designation
Fast Track is an FDA program designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and address an unmet medical need. A drug that receives Fast Track designation may be eligible for more frequent meetings and written communication with the FDA regarding its development plan, and, if relevant criteria are met, for Accelerated Approval and Priority Review. Fast Track designation also allows for Rolling Review, under which a company may submit completed sections of its marketing application for FDA review rather than waiting until every section is complete. Fast Track designation does not alter the standards for approval.
About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor advancing toward a registrational trial in first-line RAS-mutated metastatic colorectal cancer (mCRC). In a randomized Phase 2 trial, onvansertib in combination with FOLFIRI/bevacizumab (first-line standard-of-care) demonstrated dose-dependent improvements in overall response rate and progression-free survival compared to standard-of-care alone, building on findings from a prior Phase 1b/2 trial in second-line KRAS-mutated mCRC. Based on these results, the Company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab as the regimen to advance into the planned registrational trial in first-line patients with RAS-mutated mCRC.
Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC) and triple-negative breast cancer (TNBC), as well as chronic myelomonocytic leukemia (CMML) and small cell lung cancer (SCLC), both of which have received FDA Orphan Drug Designation.
About RAS-Mutated Metastatic Colorectal Cancer (mCRC)
Colorectal cancer is among the most commonly diagnosed cancers and the second-leading cause of cancer deaths in the United States, with approximately 150,000 new cases each year1. About 23% of patients have metastatic disease at diagnosis, and the five-year relative survival rate for mCRC is approximately 15%2. Mutations in the KRAS or NRAS genes occur in approximately 52% of patients with mCRC and are associated with poorer outcomes. Patients with RAS-mutated mCRC are not candidates for anti-EGFR therapies, and first-line treatment has remained largely unchanged for two decades: chemotherapy combined with bevacizumab. There are currently no therapies specifically approved for first-line pan-RAS-mutated mCRC, highlighting the need for new treatments that can improve outcomes for this population.
(Press release, Cardiff Oncology, NOV 16, 2026, View Source [SID1234674856])